Updated on 11 August 2026
EveryBaby: AI-enabled handheld device for preterm birth prediction, raising Seed to accelerate Asia clinical rollout
CEO at EveryBaby
China (Hong Kong)
About
Preterm birth: leading cause of neonatal death, ~15M births/year globally (WHO).
EveryBaby's handheld device measures cervical electrical impedance at the point of care and returns a risk score in seconds. No lab required.
Status
- UAE: Conditional Approval (DoH Abu Dhabi). PIVOTAL study Q1 2027.
- IP Protected
- Manufacturing: Tier 1 assembly partner secured.
Seeking: Seed investors, hospital networks, and distributors across GCC, ASEAN, and Greater China.
Project Location
- China (Hong Kong)
Project Website
https://www.every-baby.com/
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Feasibility Study Completed
Main Project Sector
- Technology
Technology
- Medical Technology
Investment Capital Required
- 2,500,001 to 5,000,000 USD
Interested Format of Cooperation
- Open for Negotiation
Preferred Financing Model
- Open for negotiation
Type(s) of Last Financing Round of the project (if Applicable)
- Equity (private)
Main Service(s) Required
- Financial Services
Financial Services
- Institutional Investment
- Islamic Finance
- Private Equity & Venture Capital
Attached files
Organisation
China (Hong Kong)
Similar opportunities
Project
Cannabis and Drug Breath Testing
- No
- Yes
- Debt
- Equity
- Technology
- Joint Venture
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Medical Technology
- Financial Services
- Open for negotiation
- Open for Negotiation
- Professional Services
- 500,001 to 1,000,000 USD
- Direct Equity Investment
- Institutional Investment
- Feasibility Study Completed
- Public / Alternative Financing
- Market Entry Strategic Analysis
- Private Equity & Venture Capital
- Public–private partnership / Concession
Grover Cheung
Founder & CEO at Qi Diagnostics Limited
China (Hong Kong)
Project
Seaplane Asia - seaplanes, private jets, and aircraft assets
- Yes
- Yes
- Debt
- Equity
- Operations
- Joint Venture
- Private Project
- Convertible Loan
- Equity (private)
- Financial Services
- Ports And Waterways
- Open for negotiation
- Aviation and Airports
- Open for Negotiation
- Minority Shareholdings
- Direct Equity Investment
- 25,000,001 to 50,000,000 USD
- 10,000,001 to 25,000,000 USD
- Lease / Asset Backed Financing
- Transport and Logistics Infrastructure
Dennis Keller
Group CEO at Seaplane Asia Group
China (Hong Kong)
Project
- Yes
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Health Technology
- Equity (private)
- Medical Technology
- Financial Services
- Open for Negotiation
- 5,000,001 to 7,500,000 USD
- Feasibility Study Completed
- 25,000,001 to 50,000,000 USD
- Private Equity & Venture Capital
Roger Zhang
Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited
China (Hong Kong)